RT Journal Article SR Electronic T1 Psychiatric disorders and self-harm across 26 adult cancers: cumulative burden, temporal variation, excess years of life lost and unnatural causes of deaths JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.10.07.21264703 DO 10.1101/2021.10.07.21264703 A1 Wai Hoong Chang A1 Alvina G. Lai YR 2021 UL http://medrxiv.org/content/early/2021/10/09/2021.10.07.21264703.abstract AB Background Cancer is a life-altering event causing considerable psychological distress. However, population-representative variations in the total burden of psychiatric episodes across cancer types and treatment modalities have not been examined. We sought to estimate the risk of self-harm after incident psychiatric disorder diagnosis in patients with cancer, and the risk of unnatural deaths after self-harm.Design, Setting, Participants Population-based cohort study with multiphase study designs. Population-based linked patient records in England (1998-2020) from primary care practices, hospitals, cancer registry and death registry were employed. We identified 459,542 individuals age ≥ 18 years with an incident diagnosis of a site-specific cancer of interest.Main outcome measures Using outpatient and inpatient records, we identified patients with five psychiatric disorders of interest: depression, anxiety disorder, schizophrenia, bipolar disorder and personality disorder. Cumulative burden for all psychiatric events was estimated using the mean cumulative count method. We considered 10 cancer treatment regimens, 11 chemotherapy drug classes, deprivation status and 21 non-cancer comorbidities in stratified analyses. Propensity score matching was employed to identify controls who did not have any record of a psychiatric disorder of interest. For each psychiatric disorder category, we fitted a Cox regression model to estimate the risk of self-harm. We also estimated the risk of all-cause mortality and excess years of life lost comparing patients with and without psychiatric disorders. A separate matched cohort was generated to explore the risk of suicide and unnatural deaths following self-harm.Results Depression was the most common psychiatric disorder in patients with cancer, where some of the highest cumulative burdens were observed in patients with testicular cancer (98.05 per 100 individuals [CI: 83.08-127.25]), cervical cancer (78.74 [73.61-90.14]) and Hodgkin lymphoma (69.87 [61.05-69.48]) by age 60. Patients who received chemotherapy, radiotherapy and surgery had the highest cumulative burden of psychiatric disorders, while patients who received radiotherapy alone had the lowest burden. Patients treated with alkylating agent chemotherapeutics had the highest burden of psychiatric disorders while those treated with kinase inhibitors had the lowest burden. Among patients with cancer, 5,683 individuals were identified as having an incident self-harm episode. A previous diagnosis of psychiatric disorder before self-harm was at least twice as prevalent than a subsequent diagnosis of psychiatric disorder where the prevalence ratio was the highest in patients with brain tumours (5.36, CI: 4.57-6.14). Younger individuals were more likely to be diagnosed with mental illness before the first self-harm episode. However, individuals from more deprived regions (2.46, CI: 2.32-2.60) and individuals with ≥4 pre-existing comorbidities (2.19, CI: 1.92-2.46) were less likely to be diagnosed with mental illness before self-harm. Patients with mental illness had a higher cumulative burden of self-harm events compared with matched controls. All mental illnesses were associated with an increased risk of subsequent self-harm, where the highest risk was observed within 12 months of the mental illness diagnosis. Risks of self-harm during the first year in matched cohorts were as follow: depression (adjusted HR 44.1, CI: 34.0-57.1), anxiety disorder (HR 21.1, CI: 16.4-27.0) and schizophrenia (HR 7.5, CI: 5.0-11.2). Patients with cancer and psychiatric disorder experienced excess years of life lost. Patients who harmed themselves were 6.8 times more likely to die of unnatural causes of death compared with controls within 12 months of self-harm (HR 6.8, CI: 4.3-10.7). The risk of unnatural death after 12 months was markedly lower (HR 2.0, CI: 1.5-2.7).Conclusions This study quantifies the total burden of psychiatric events and self-harm in patients with cancer. The cumulative burden of psychiatric events varies across cancer type, treatment regimen and chemotherapy type. Incident psychiatric disorder diagnoses were significantly associated with increased risk of subsequent self-harm, where risks varied across psychiatric diagnostic categories and follow-up periods. Patients who harm themselves experienced the highest risk of dying from unnatural deaths within the first year of self-harm. We provide an extensive knowledge base to help inform collaborative cancer-psychiatric care initiatives by prioritising patients who are most at risk.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAGL is supported by funding from the Wellcome Trust (204841/Z/16/Z), National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (BRC714/HI/RW/101440), the Academy of Medical Sciences (SBF006\1084), NIHR Great Ormond Street Hospital Biomedical Research Centre (19RX02) and the Health Data Research UK Better Care Catalyst Award (CFC0125). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was obtained from the Medicines Healthcare Regulatory Authority Independent Scientific Advisory Committee (19_222 21_000593).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.